Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Nu Holdings Ltd (NU) Price & Performance

Inovio Pharmaceuticals IncTrade
Nu Holdings LtdTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Nu Holdings Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Nu Holdings Ltd trades at $13.44 (market cap $65.94B). The key difference: Nu Holdings Ltd is far larger — about 839.5× Inovio Pharmaceuticals Inc's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INONU
Market Cap
$78.55M$65.94B
Sector
HealthFinancials
52-Week High
$2.87$18.76
52-Week Low
$0.66$11.60
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Nu Holdings Ltd

NU stock trades at $13.86, up 0.14% today, with a bullish technical signal despite recent earnings misses. Revenue grew from $3.0B in 2022 to $10.6B in 2025, with net income turning positive to $2.9B. The company's expansion in Brazil and Mexico, including a pending banking license acquisition (PYMNTS, 2026-07-22), supports growth. Analysts maintain a buy consensus with a $14.98 target, though competition and Latin American market risks persist.

Outlook remains positive due to strong fundamentals and growth trajectory, but investors face risks from rising competition and regional volatility. The upcoming Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) serves as a key catalyst, with expectations of $0.1984 EPS. Institutional activity is mixed, with some trimming stakes while others increase holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Nu Holdings Ltd

Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.

Read more on NU